Yufei Liu

Targeting antibody-inaccessible immune resistance with small-molecule immunotherapy.

ICIs have revolutionized cancer treatment; however, the achievement of sustained clinical benefits is confined to a subset of patients due to inherent and acquired resistance mechanisms. Accumulating evidence suggests that tumor immune evasion is often sustained through intracellular, metabolic, epigenetic, and myeloid...